Search

Search Constraints

You searched for: Author/Creator Schroeder, Mark A.

Search Results

1. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft‐versus‐host disease. (11th June 2022)

2. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Issue 8 (28th April 2014)

3. A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. Issue 6 (12th May 2021)

4. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Issue 2 (28th January 2023)

5. A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Issue 12 (15th October 2021)

8. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results. Issue 11 (9th September 2018)

9. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. (2021)

10. Impact of a 40‐Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. (December 2021)